<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of infection in exacerbations of chronic obstructive pulmonary disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of infection in exacerbations of chronic obstructive pulmonary disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of infection in exacerbations of chronic obstructive pulmonary disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjay Sethi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy F Murphy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julio A Ramirez, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most exacerbations of chronic obstructive pulmonary disease (COPD) are caused by respiratory tract infections. Empiric antibiotic therapy is indicated for patients who are most likely to have a bacterial infection causing the exacerbation and for those who are most ill.</p><p>The role of antibiotic therapy in exacerbations of COPD will be reviewed here. The evaluation for infection in exacerbations of COPD and other aspects of management (eg, bronchodilators, glucocorticoids, oxygen, and mechanical ventilation) are discussed separately. (See  <a class="medical medical_review" href="/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease"</a> and  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="headingAnchor" id="H1152952685"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The Global Initiative for Chronic Obstructive Lung Disease guidelines define an exacerbation of COPD as an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days, which may be accompanied by tachypnea and/or tachycardia, and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways [<a href="#rid1">1,2</a>].</p><p>The three cardinal symptoms that characterize an exacerbation of COPD are [<a href="#rid1">1,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased dyspnea</p><p class="bulletIndent1"><span class="glyph">●</span>Increased sputum volume and/or viscosity</p><p class="bulletIndent1"><span class="glyph">●</span>Increased sputum purulence</p><p></p><p>Other findings that may accompany the cardinal symptoms of an exacerbation of COPD (eg, tachypnea, chest discomfort, fatigue, sleep disturbance, decline in pulmonary function) are discussed separately. (See  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.)</p><p class="headingAnchor" id="H436716092"><span class="h1">INDICATIONS FOR ANTIBACTERIAL THERAPY</span></p><p class="headingAnchor" id="H2076469583"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Empiric antibiotic therapy is indicated for patients who are most likely to have a bacterial infection causing the exacerbation and for those who are most ill [<a href="#rid1">1,4</a>]. In general, we determine the need for antibiotics based on the number of cardinal symptoms present, and the need for hospitalization and/or ventilatory support [<a href="#rid1">1,5-7</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest empiric antibiotic treatment in patients with a COPD exacerbation and ≥2 of 3 cardinal symptoms: increased dyspnea, increased sputum volume/viscosity, or increased sputum purulence <strong>or</strong> a COPD exacerbation requiring hospitalization and/or ventilatory support (either invasive or noninvasive).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do <strong>not</strong> initiate antibiotic therapy in patients with a COPD exacerbation and only 1 of 3 cardinal symptoms who do not require hospitalization or ventilatory support. New onset of increased wheezing may serve as an additional negative predictor for bacterial infection; therefore, if it is a prominent finding, it steers us away from antibiotic use [<a href="#rid8">8</a>].</p><p></p><p>Antibiotics are also indicated for patients with concurrent pneumonia (ie, those with fever, signs of consolidation on chest examination and/or chest imaging). Selection of an antibiotic regimen for patients with pneumonia differs from COPD exacerbations and is discussed separately. (See  <a class="medical medical_review" href="/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H1256872202"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>Our approach is based upon randomized trials and large cohort studies demonstrating that prompt, appropriate antibiotic use improves clinical outcomes for selected patients with COPD exacerbations [<a href="#rid3">3,9-16</a>]. The benefit is greatest in severely ill patients and those with a greater number of symptoms but appears to diminish as the severity of illness declines. In a meta-analysis of five randomized trials evaluating 803 patients hospitalized with an acute COPD exacerbation, antibiotic use was associated with reduced treatment failure when compared with placebo (risk ratio [RR] 0.76, 95% CI 0.58-1.0) [<a href="#rid9">9</a>]. The benefits of antibiotic treatment were most prominent in a single trial evaluating 93 intensive care unit (ICU) patients, which showed a reduction in all-cause mortality (4 versus 22 percent with placebo) in addition to reductions in treatment failure, duration of mechanical ventilation, length of ICU stay, and need for additional courses of antibiotics [<a href="#rid10">10</a>]. In a cohort study evaluating &gt;84,000 hospitalized patients with COPD exacerbations, the risk of treatment failure was lower when antibiotics were given in the first two hospital days compared with later treatment or no treatment (odds ratio [OR] 0.87, 95% CI 0.82-0.92) [<a href="#rid12">12</a>]. Multivariate analysis of this cohort demonstrated that antibiotic treatment was associated with decreased risk of in-hospital mortality (OR 0.60, 95% CI 0.50-0.73) and a substantial reduction in the risk of 30-day readmission for COPD (OR 0.87, 95% CI 0.79-0.96) [<a href="#rid14">14</a>].</p><p>Although meta-analyses of randomized trials and large cohort studies have also found reduced treatment failure rates with antibiotic use in outpatients [<a href="#rid9">9,11</a>], the benefit appears to be greatest in those with a higher number of cardinal symptoms. This finding is best supported by the Anthonisen trial, one of the largest and more rigorous randomized trials evaluating the efficacy for antibiotics for COPD exacerbations to date [<a href="#rid3">3</a>]. The trial evaluated 173 patients and a total of 362 COPD exacerbations over a three and a half year period. Antibiotic therapy was associated with increased clinical improvement (defined as resolution of symptoms without additional intervention) compared with placebo (68 versus 55 percent). The greatest effect was observed in patients who presented with increased dyspnea, sputum production, and sputum purulence when compared with placebo (63 versus 43 percent); benefit was least evident in patients with only one of these three symptoms (75 versus 70 percent). This observation serves as the foundation for the antibiotic treatment indications outlined above.</p><p>Based upon these studies, most clinical practice guidelines recommend antibiotic treatment of moderate to severe exacerbations for outpatients and patients who require hospitalization but not routinely for those with mild exacerbations in the outpatient setting [<a href="#rid1">1</a>]. Our approach is similar to but varies slightly from the strategy outlined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), which recommends antibiotic therapy for patients who have the following features: a severe exacerbation requiring mechanical ventilation (noninvasive or invasive), an exacerbation with all three cardinal symptoms, or an exacerbation with two of these three symptoms if sputum purulence is one of the symptoms [<a href="#rid1">1,3,17</a>]. While some studies suggest that sputum purulence is associated with an increased likelihood of infection [<a href="#rid18">18,19</a>], this finding is not consistent across studies [<a href="#rid20">20,21</a>], and we do not consider this finding alone to be clearly predictive of need for antibiotic treatment [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H646863081"><span class="h2">CRP and procalcitonin</span><span class="headingEndMark"> — </span>Multiple studies have addressed use of serum biomarkers, such as C-reactive protein (CRP) and procalcitonin, to help determine the need for antibiotic treatment in patients with COPD exacerbations [<a href="#rid24">24-29</a>]. However, study results do not clearly and consistently demonstrate that use of either assay adds value to clinical judgment alone; we generally do not use them to guide treatment decisions. (See  <a class="medical medical_review" href="/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease", section on 'Procalcitonin and C-reactive protein'</a> and  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Acute exacerbations of chronic obstructive pulmonary disease'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">EMPIRIC ANTIBACTERIAL TREATMENT</span></p><p class="headingAnchor" id="H334582942"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>We use a "risk stratification" approach when selecting initial empiric antibiotic therapy for the treatment of acute exacerbations of COPD [<a href="#rid30">30,31</a>]. We categorize patients based on treatment setting (eg, outpatient versus inpatient), risk for poor clinical outcomes, and risk for infection with <em>Pseudomonas</em>  (<a class="graphic graphic_algorithm graphicRef66357 graphicRef53537" href="/d/graphic/66357.html" rel="external">algorithm 1A-B</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for poor outcomes</strong> – Patients with greater underlying COPD severity are at higher risk for poor outcomes if initial antibiotic therapy is inadequate. We thus use a broader empiric regimen for such patients. Risk factors for poor outcomes include [<a href="#rid32">32-34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid conditions (especially heart failure or ischemic heart disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe underlying COPD (forced expiratory volume in one second [FEV<sub>1</sub>] &lt;50 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Frequent exacerbations of COPD (ie, ≥2 exacerbations per year)</p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization for an exacerbation within the past three months</p><p class="bulletIndent2"><span class="glyph">•</span>Receipt of continuous supplemental oxygen</p><p></p><p class="bulletIndent1">Older age (eg, age ≥65 years) is also associated with poorer outcomes and/or risk of infection with drug-resistant pathogens. While not a strict indication for broadening antibiotic therapy, we consider older age as additive to the risk factors listed above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for pseudomonal infection</strong> – Patients with greater underlying COPD severity are also at risk for infection with <em>Pseudomonas</em>. Specific factors associated with an increased risk of <em>Pseudomonas</em> infection include [<a href="#rid35">35-38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic colonization or previous isolation of <em>Pseudomonas aeruginosa </em>from sputum</p><p class="bulletIndent2"><span class="glyph">•</span>Very severe COPD (FEV<sub>1</sub> &lt;30 percent predicted)</p><p class="bulletIndent2"><span class="glyph">•</span>Bronchiectasis on chest imaging (eg, chest radiograph, computed tomography)</p><p class="bulletIndent2"><span class="glyph">•</span>Broad-spectrum antibiotic use within the past three months</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic systemic glucocorticoid use</p><p></p><p>This approach to risk stratification promotes judicious antibiotic use by reserving broader spectrum empiric regimens for patients with greater underlying COPD severity [<a href="#rid32">32,39,40</a>]. Although it has not been validated in clinical trials, similar approaches are used for the treatment of other infectious diseases (eg, community-acquired pneumonia, acute rhinosinusitis) [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H1105234843"><span class="h2">Antibiotic selection</span><span class="headingEndMark"> — </span>Empiric antibiotic regimens are designed to target the most likely infecting pathogens  (<a class="graphic graphic_table graphicRef70203" href="/d/graphic/70203.html" rel="external">table 1</a>). Specific antibiotic selection and need for sputum Gram stain and culture vary based on risk for poor clinical outcomes, risk for infection with <em>Pseudomonas</em>, and treatment setting  (<a class="graphic graphic_algorithm graphicRef66357 graphicRef53537" href="/d/graphic/66357.html" rel="external">algorithm 1A-B</a>) [<a href="#rid1">1,34,37</a>]. Determining need for hospitalization in patients with COPD exacerbations is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Triage to home or hospital'</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120461">(Related Pathway(s):  <a class="utd-content-120461" href="/pathway/120461?topicRef=7019&amp;source=see_link">Chronic obstructive pulmonary disease: Identifying patients with an acute exacerbation who warrant hospitalization</a>.)</span></p><p class="headingAnchor" id="H835040109"><span class="h3">Outpatients</span><span class="headingEndMark"> — </span>Antibiotic therapy is indicated for outpatients with COPD exacerbations and an increase in ≥2 of 3 cardinal symptoms: dyspnea, sputum volume/viscosity, or sputum purulence  (<a class="graphic graphic_algorithm graphicRef66357" href="/d/graphic/66357.html" rel="external">algorithm 1A</a>) [<a href="#rid34">34,37</a>]. Patients with only one cardinal symptom generally do not require antibiotic therapy. (See <a class="local">'Indications for antibacterial therapy'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-122850">(Related Pathway(s):  <a class="utd-content-122850" href="/pathway/122850?topicRef=7019&amp;source=see_link">Chronic obstructive pulmonary disease: Empiric antimicrobial therapy for outpatients with acute exacerbations</a>.)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For outpatients who do not have risk factors for poor outcomes or </strong><strong><em>Pseudomonas</em></strong><strong> infection</strong>, we target <em>Streptococcus pneumoniae, Haemophilus influenzae</em>, and <em>Moraxella catarrhalis</em> and select among the following options: a macrolide (ie, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>) <strong>or</strong> a second- or third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a>, <a class="drug drug_general" data-topicid="9224" href="/d/drug information/9224.html" rel="external">cefpodoxime</a>, <a class="drug drug_general" data-topicid="8602" href="/d/drug information/8602.html" rel="external">cefdinir</a>). <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> is a reasonable alternative to these agents but not first line because trial data suggest it may be less effective [<a href="#rid43">43</a>]. We no longer use <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> based on a randomized trial showing minimal benefit [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For outpatients who have risk factors for poor outcomes (but no increased risk for </strong><strong><em>Pseudomonas</em></strong><strong> infection)</strong>  (<a class="graphic graphic_table graphicRef126161" href="/d/graphic/126161.html" rel="external">table 2</a>), we broaden the initial regimen to include treatment for macrolide-resistant <em>S. pneumoniae</em> and to enhance eradication of<em> H. influenzae</em>. For these patients, we select either <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> or a respiratory fluoroquinolone (ie, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For outpatients who have risk factors for poor outcomes and a risk for </strong><strong><em>Pseudomonas </em></strong><strong>infection</strong><em> </em> (<a class="graphic graphic_table graphicRef126162" href="/d/graphic/126162.html" rel="external">table 3</a>)<em>,</em> we generally treat with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>. Because fluoroquinolone resistance is prevalent among <em>P. aeruginosa s</em>trains, we also obtain a sputum Gram stain and culture with susceptibility testing for these patients to help guide subsequent management decisions (eg, change in therapy based on susceptibility testing for those who do not respond to empiric treatment). (See <a class="local">'Follow-up'</a> below.)</p><p></p><p class="bulletIndent1">Some experts add <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> or another agent with better activity against <em>S. pneumoniae</em> to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> for broader empiric treatment. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> is a reasonable alternative for patients who have risk factors for <em>Pseudomonas </em>infection but no prior history of positive cultures for <em>Pseudomonas</em>. Although levofloxacin is less potent than <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> for the treatment of <em>Pseudomonas</em>, it has comparatively greater activity against other common pathogens (<em>S. pneumoniae</em> and <em>M. catarrhalis)</em>. <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> is not recommended for patients with risk factors for <em>Pseudomonas</em>, as it has little activity against this pathogen.</p><p></p><p>In most cases, several treatment options are available. We select among antibiotic options based on the patient's previous response to that agent, patient allergies and intolerances, the drug's adverse event profile, drug interactions, susceptibility pattern of organisms isolated in recent sputum cultures (if available), and local antimicrobial resistance patterns. In some instances, local antibiotic resistance rates can be determined by obtaining an antibiogram from a local hospital. However, this information is not always available or readily accessible.</p><p>In general, we also avoid using the same antibiotic class more than once within a three-month period. Antibiotic exposure in the previous three months is one of the best predictors of pathogens resistant to that drug class in an individual patient. For example, if a patient has responded well and tolerated a certain antibiotic and that antibiotic was not used within the past three months, then that agent (or one in the same class) is a good choice. However, if that agent was used within the past three months, then an agent of a different class should be selected.</p><p>The antibiotic selection outlined above is based on the susceptibility profiles and evolving resistance patterns of the most common pathogens. For example, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, which was favored in the past, is no longer a recommended agent because it is inactivated by many nontypeable <em>H. influenzae</em> and most strains of <em>M. catarrhalis</em>. <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> resistance among <em>S. pneumoniae</em> is prevalent in some regions, and it does not appear to improve clinical outcomes when compared with systemic glucocorticoids alone [<a href="#rid44">44,45</a>]; thus, it is also no longer first line. This approach is further supported by a meta-analysis of 12 randomized trials evaluating &gt;2100 patients, which showed that amoxicillin-clavulanic acid, macrolides, second- or third-generation cephalosporins, and fluoroquinolones were more effective than amoxicillin, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, pivampicillin, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and doxycycline for the treatment of COPD exacerbations (odds ratio [OR] 0.51, 95% CI 0.34-0.75) [<a href="#rid46">46</a>]. Treatment success was defined as resolution or improvement of symptoms.</p><p>Several studies have compared the efficacy of macrolides, fluoroquinolones, and <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> with one another [<a href="#rid43">43,47,48</a>]. One meta-analysis of 19 trials, evaluating &gt;7400 patients with COPD exacerbations, compared the effectiveness of macrolides (ie, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>), fluoroquinolones (ie, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>), and amoxicillin-clavulanate [<a href="#rid43">43</a>]. Antibiotic selection did not affect short-term treatment success, defined as resolution or improvement of symptoms. However, among patients who had a pathogen isolated from sputum at presentation, treatment success was lower for macrolides when compared with fluoroquinolones (OR 0.47, 95% CI 0.31-0.69). Recurrence, in the 26 weeks following therapy, was also less frequent in patients who were treated with fluoroquinolones compared with macrolides. The reduction in treatment success observed with macrolides may be related to their limited ability to eradicate <em>H. influenzae</em>. Amoxicillin-clavulanate had similar efficacy when compared with other agents but was associated with more adverse effects (mostly diarrhea) than the other drugs. In a subsequent randomized trial evaluating &gt;500 patients with exacerbations of COPD, moxifloxacin and amoxicillin-clavulanate appeared to have similar overall efficacy [<a href="#rid47">47</a>]. However, clinical failure rates were lower with moxifloxacin when the analysis was limited to patients with a pathogen isolated from sputum (19 versus 25 percent). Adverse effects associated with fluoroquinolone use are discussed separately. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones"</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H2360992340"><span class="h3">Hospitalized patients</span><span class="headingEndMark"> — </span>For patients hospitalized for treatment of a COPD exacerbation (who lack clinical and radiographic suspicion for pneumonia), we primarily base empiric antibiotic selection on the risk for <em>Pseudomonas</em>  (<a class="graphic graphic_algorithm graphicRef53537" href="/d/graphic/53537.html" rel="external">algorithm 1B</a>)<em>.</em> We select among appropriate options based on the patient's previous response to that agent, patient allergies and intolerances, the drug's adverse event profile, drug interactions, local antimicrobial resistance patterns, and the susceptibility pattern of organisms isolated in recent sputum cultures (if available).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most inpatients without risk factors for </strong><strong><em>Pseudomonas</em></strong><strong> infection</strong>, we select either a respiratory fluoroquinolone (ie, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally or intravenously [IV] once daily or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally or IV once daily) or a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For most inpatients with risk factors for </strong><strong><em>Pseudomonas</em></strong><strong> infection</strong>, we select one of the following: <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, or <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4.5 g IV every six hours). For those who cannot tolerate these agents, alternatives include <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>, certain carbapenems (eg, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>), and aminoglycosides. Each comes with relative disadvantages when compared with the antipseudomonal beta-lactams  (<a class="graphic graphic_table graphicRef135124" href="/d/graphic/135124.html" rel="external">table 4</a>). We generally select among them based on local epidemiology, prior susceptibility testing results, drug interactions, and patient comorbidities or intolerances. Two agents are often needed for empiric treatment. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p></p><p>For all hospitalized patients who are able to produce a good-quality sputum sample, we obtain a Gram stain and culture to help guide management. For most others, we do not obtain microbiologic testing on sputum because it has limited diagnostic accuracy and results are unlikely to change management. (See  <a class="medical medical_review" href="/d/html/108592.html" rel="external">"Evaluation for infection in exacerbations of chronic obstructive pulmonary disease", section on 'When to obtain sputum studies'</a>.)</p><p>Patients with clinical concern for concurrent pneumonia should be treated with empiric antibiotic regimens based on the suspected pathogens, severity of illness, and type of pneumonia. (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p>Additional detail on the antibiotic selection for patients with known or suspected pseudomonal infections are provided separately. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p class="headingAnchor" id="H1215153261"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of therapy for patients who are clinically improving is generally five days for outpatients and five to seven days for hospitalized patients. However, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> can be given for as few as three days when administered at a dose of 500 mg orally daily because of its long half-life. Patients who are initially started on parenteral antibiotics should be switched to an oral regimen when able to take medications orally.</p><p>A meta-analysis that compared five days with seven or more days of antimicrobial therapy (fluoroquinolones, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>, or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>) for exacerbations of COPD found no difference in outcome between the two groups, although there were fewer adverse events among patients who received a five-day course [<a href="#rid49">49</a>].</p><p>Some experts use procalcitonin, a biomarker that rises in response to bacterial infections, to guide antibiotic duration. However, clinical utility and safety of using procalcitonin to guide therapy in patients with COPD exacerbations is not firmly established and its use is controversial. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections", section on 'Acute exacerbations of chronic obstructive pulmonary disease'</a>.)</p><p class="headingAnchor" id="H619349333"><span class="h1">RESPIRATORY VIRUS TREATMENT</span></p><p class="headingAnchor" id="H2218383221"><span class="h2">Influenza</span><span class="headingEndMark"> — </span>Antiviral therapy is usually indicated for patients whose acute exacerbations of COPD have been triggered by influenza virus. However, the benefits of antiviral therapy diminish with time; thus, for patients presenting ≥72 hours after illness onset, we take the patient's clinical trajectory (eg, worsening/improving) into account when deciding to prescribe. For patients with influenza who also meet criteria for antibacterial treatment (ie, ≥2 cardinal symptoms, need for hospitalization and/or ventilatory support), we treat with both antiviral and antibacterial therapy.</p><p>Inhaled <a class="drug drug_general" data-topicid="10323" href="/d/drug information/10323.html" rel="external">zanamivir</a> is contraindicated in this patient population due to the risk of airway reactivity. Other agents, such as oral <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a>, oral <a class="drug drug_general" data-topicid="119458" href="/d/drug information/119458.html" rel="external">baloxavir</a>, or, in certain situations, intravenous <a class="drug drug_general" data-topicid="9527" href="/d/drug information/9527.html" rel="external">peramivir</a> or zanamivir (not available in the United States) can be used. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="headingAnchor" id="H164062497"><span class="h2">Coronavirus disease 2019</span><span class="headingEndMark"> — </span>COPD increases the morbidity and mortality associated with coronavirus disease 2019 (COVID-19; caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) and we test all COPD patients with symptoms of an exacerbation for COVID-19. </p><p>Standard treatment of the exacerbation with bronchodilators, systemic corticosteroids, and antibiotics should not be altered in patients with both COPD and COVID-19 [<a href="#rid50">50</a>]. However, these patients need to be observed closely for deterioration. Given their age and comorbidity, patients with COPD and COVID-19 are likely to be candidates for COVID-19 specific therapy. (See  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="headingAnchor" id="H3687614106"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Most patients should demonstrate some improvement in 48 to 72 hours of starting antibiotic therapy. For those who fail to improve, we generally obtain a sputum culture (if not already obtained) to help guide any subsequent changes in antibiotic treatment, reevaluate our approach to other aspects of care (eg, bronchodilators, need for mechanical ventilation), consider potential contributing comorbidities, and broaden our differential diagnosis to include other cardiopulmonary disorders (eg, pneumonia, heart failure, lung cancer). (See  <a class="medical medical_review" href="/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Adjusting therapy for poor response'</a> and  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H489947517"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>Patients with COPD should be vaccinated against seasonal influenza virus (annually), SARS CoV-2, and pneumococcus  (<a class="graphic graphic_table graphicRef86782" href="/d/graphic/86782.html" rel="external">table 5</a>).  </p><p>The evidence supporting vaccination of patients with COPD includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The utility of influenza vaccination is well established for reducing both the rate and severity of symptoms due to influenza, including respiratory symptoms. A meta-analysis of 11 trials, including 6 specifically performed in patients with COPD, found a significant reduction in the number of exacerbations per patient compared with placebo [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For pneumococcal vaccination, a meta-analysis of 12 randomized trials evaluated the efficacy of <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a> on 2171 patients with COPD [<a href="#rid52">52</a>]. Analysis of five trials showed a reduction in the rates of community-acquired pneumonia with vaccination (odds ratio [OR] 0.61, 95% CI 0.42-0.89), and four trials showed a reduction in rates of COPD exacerbation (OR 0.60, 95% CI 0.39-0.93). There were no significant differences in all-cause or cardiorespiratory mortality, although event rates were low. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p></p><p>Patients with COPD should also receive other vaccines according to the schedule summarized in the following figure  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>); in particular, vaccine uptake for pertussis is low and incidence is rising. (See  <a class="medical medical_review" href="/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention", section on 'Vaccination'</a>.)</p><p>All patients who lack contraindications should be vaccinated against SARS-CoV-2. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H489947524"><span class="h2">Prophylactic macrolides</span><span class="headingEndMark"> — </span>We do not routinely use prophylactic macrolides or other antibiotics for the long-term care of patients with COPD. For most patients, the benefits of long-term antibiotic use do not outweigh the risks. However, for selected patients with severe COPD with frequent exacerbations (≥2 per year) despite optimal medical management (long-acting bronchodilators, inhaled glucocorticoids, pulmonary rehabilitation, smoking cessation), macrolide prophylaxis may be advantageous. The risks associated with the development of antibiotic resistance should be taken into account when deciding to use long-term prophylaxis. When considering prescription, we carefully weigh the potential benefit against the risk of long-term macrolide use (eg, QT prolongation, other cardiovascular events, <em>Clostridioides difficile </em>infection). (See  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a>.)</p><p>When prescribing a macrolide for long-term prophylaxis, we typically use <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, which can be given as 250 mg daily [<a href="#rid53">53</a>] or at a lower dose of 250 to 500 mg three times per week [<a href="#rid54">54-57</a>]. We often use 250 mg three times per week to reduce adverse effects, although this dose is less well studied. <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">Erythromycin</a> (500 mg two times per day) is an alternative [<a href="#rid1">1</a>]. While the optimal duration of therapy is not known, a 12-month course is commonly used [<a href="#rid1">1</a>]. If there is suspicion for <em>Mycobacterium avium </em>complex<em> </em>(MAC) infection based on symptoms or radiological signs (bronchiectasis, tree in bud, chronic opacities on chest radiograph or computed tomography), sputum or bronchoscopic cultures for MAC should be obtained prior to initiation of macrolides; their use is not recommended if the cultures are positive. (See  <a class="medical medical_review" href="/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections", section on 'Clinical manifestations'</a>.)</p><p>The benefit of macrolides is attributed to their immunomodulatory effects in addition to their potential to prevent infection [<a href="#rid58">58,59</a>]. In a systematic review of 14 randomized trials evaluating 3932 patients with moderate-to-severe COPD, the proportion of patients experiencing ≥1 exacerbation was reduced when comparing prophylactic antibiotic use (primarily macrolides) with placebo (OR 0.57, 95% CI 0.42-0.78) [<a href="#rid58">58</a>]. A marginal improvement in quality-of-life measures was detected; trends toward improvement in the number of hospital admissions, change in forced expiratory volume in one second (FEV<sub>1</sub>), serious adverse events, and all-cause mortality were observed but were not statistically significant.</p><p>The benefits and risks of long-term macrolide use are well illustrated in one of the randomized trials included in the meta-analysis [<a href="#rid53">53,58</a>]. In this trial, 1142 patients with COPD were randomly assigned to receive <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 250 mg orally daily or placebo for one year in addition to their usual COPD regimen [<a href="#rid53">53</a>]. The following findings were observed:</p><p class="bulletIndent1"><span class="glyph">●</span>The median time to first COPD exacerbation was significantly longer among the patients who received <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> compared with those who received placebo (266 versus 174 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who received <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> had a significant (but modest) reduction in the frequency of COPD exacerbations compared with those who received placebo (1.48 versus 1.83 exacerbations per patient-year; hazard ratio 0.73, 95% CI 0.63-0.84).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who received <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> had a significantly higher rate of nasopharyngeal colonization with macrolide-resistant bacteria (<em>Staphylococcus aureus</em>, <em>S. pneumoniae</em>, <em>Haemophilus</em> spp, <em>Moraxella</em> spp) than those who received placebo (81 versus 41 percent). Lower airway and enteric microbiology were not monitored, so the emergence of macrolide-resistant strains in these relevant sites was not assessed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hearing decrements (assessed by audiometry) were more common in the <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> group than the placebo group (25 versus 20 percent). However, hearing loss associated with azithromycin usually results from long-term use and is reversible.</p><p></p><p>Patients with resting tachycardia, hearing impairment, and those with or at risk for a prolonged QT interval were excluded from participating. Thus, the risks of long-term use may be higher when used in the general COPD population.</p><p>Other antibiotics, particularly <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, also have demonstrated some efficacy for preventing COPD exacerbations [<a href="#rid17">17</a>]. However, we typically reserve their use for the treatment of infections in order to avoid fluoroquinolone-related adverse effects and the selection of fluoroquinolone-resistant bacteria [<a href="#rid60">60</a>]. In one trial comparing pulsed moxifloxacin (400 mg orally daily for five days every eight weeks for six cycles [total duration of 48 weeks]) in 1157 patients with COPD at high risk for recurrent exacerbations, the risk of COPD exacerbation was lower with moxifloxacin, both in the per-protocol analysis (OR 0.75, 95% CI 0.565-0.994) and in the intent-to-treat analysis (OR 0.81, 95% CI 0.645-1.008) [<a href="#rid17">17</a>]. A larger benefit was observed in those with purulent or mucopurulent sputum production (OR 0.55, 95% CI 0.36-0.84) in post-hoc analysis. Gastrointestinal adverse effects were more frequent with moxifloxacin; however, <em>C. difficile</em> infections were not observed. Sustained emergence of moxifloxacin-resistant strains was not observed in sputum or in enteric flora.</p><p class="headingAnchor" id="H1248309716"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> –<strong> </strong>Most exacerbations of chronic obstructive pulmonary disease (COPD) are caused by respiratory tract infections. Empiric antibiotic therapy is indicated for patients who are most likely to have a bacterial infection causing the exacerbation and for those who are most ill. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical characteristics </strong>– An exacerbation of COPD is an event characterized by dyspnea and/or cough and sputum that worsens over ≤14 days and is often associated with increased airway or systemic inflammation. Most exacerbations of COPD are due to respiratory infection. Cardinal symptoms of a COPD exacerbation include (see <a class="local">'Introduction'</a> above and <a class="local">'Definitions'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase in dyspnea</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in sputum volume and/or viscosity</p><p class="bulletIndent2"><span class="glyph">•</span>Increase in sputum purulence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to treat with antibiotics </strong>–<strong> </strong>We typically determine the need for antibiotics based on the number of cardinal symptoms present and the need for hospitalization and/or ventilatory support. The benefit of empiric antibiotic treatment is greatest in severely ill patients and those with a greater number of symptoms but appears to diminish as the severity of illness declines. (See <a class="local">'Indications for antibacterial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest empiric antibiotic treatment in patients with a COPD exacerbation and ≥2 of 3 cardinal symptoms: increased dyspnea, increased sputum volume/viscosity, or increased sputum purulence <strong>or</strong> a COPD exacerbation requiring hospitalization <strong>and/or</strong> ventilatory support (either invasive or noninvasive) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do <strong>not</strong> initiate antibiotic therapy in patients with a COPD exacerbation and only one of three cardinal symptoms who do not require hospitalization or ventilatory support. New onset of increased wheezing may serve as an additional negative predictor for bacterial infection; therefore, if it is a prominent finding, it steers us away from antibiotic use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification to guide antibiotic selection </strong>–<strong> </strong>We use a "risk stratification" approach when selecting initial empiric antibiotic therapy for the treatment of acute exacerbations of COPD. We categorize patients based on treatment setting (eg, outpatient versus inpatient), risk for poor clinical outcomes  (<a class="graphic graphic_table graphicRef126161" href="/d/graphic/126161.html" rel="external">table 2</a>), and risk for infection with <em>Pseudomonas </em> (<a class="graphic graphic_table graphicRef126162" href="/d/graphic/126162.html" rel="external">table 3</a>). (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotic regimens </strong>– Empiric antibiotic regimens are designed to target the most likely infecting pathogens  (<a class="graphic graphic_table graphicRef70203" href="/d/graphic/70203.html" rel="external">table 1</a>); specific selection varies based on the patient's risk status  (<a class="graphic graphic_algorithm graphicRef66357 graphicRef53537" href="/d/graphic/66357.html" rel="external">algorithm 1A-B</a>). When selecting an antibiotic, we take into account the patient's prior antibiotic exposure, prior clinical response to specific antibiotics, allergies and intolerances, drug interactions, the drug's adverse event profile, and the susceptibility pattern of organisms isolated in recent sputum cultures (if available). (See <a class="local">'Antibiotic selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of antibiotics </strong>– The duration of therapy is generally five days for outpatients and five to seven days for most hospitalized patients. However, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> can be given for as few as three days when administered at a dose of 500 mg orally daily because of its long half-life. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral treatment </strong>– Patients with COPD are at increased risk for complications of influenza, so antiviral therapy (eg, oral <a class="drug drug_general" data-topicid="9460" href="/d/drug information/9460.html" rel="external">oseltamivir</a> or an intravenous agent) may be appropriate for exacerbations triggered by influenza virus, depending on timing and susceptibility patterns. Inhaled <a class="drug drug_general" data-topicid="10323" href="/d/drug information/10323.html" rel="external">zanamivir</a> is contraindicated in this patient population due to the risk of airway reactivity. Similarly, patients with COPD and COVID-19 are likely to be candidates for COVID-19-specific therapy. (See <a class="local">'Respiratory virus treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination </strong>– To prevent future exacerbations, patients with COPD should be vaccinated against influenza and pneumococcus, according to the following schedule  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>). All patients who lack contraindications should also be vaccinated against SARS-CoV-2. (See <a class="local">'Vaccination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrolide prophylaxis for selected patient with severe COPD </strong>– We do not routinely use prophylactic macrolides or other antibiotics for the long-term care of patients with COPD. For most patients, the benefits of long-term antibiotic use do not outweigh the risks. However, for selected patients with severe COPD and frequent exacerbations (≥2 per year) despite optimal medical management (bronchodilators, inhaled glucocorticoids, pulmonary rehabilitation, smoking cessation), macrolide prophylaxis may be advantageous. <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> can be given as 250 mg daily or at a lower dose of 250 to 500 mg three times per week. We often use 250 mg three times per week to reduce adverse effects. (See <a class="local">'Prophylactic macrolides'</a> above.)</p><p></p><p class="headingAnchor" id="H4269480283"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204:1251.</a></li><li><a class="nounderline abstract_t">Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing. July 2018. https://www.nice.org.uk/guidance/indevelopment/gid-ng10115/documents (Accessed on July 18, 2018).</li><li><a class="nounderline abstract_t">Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010; 13:965.</a></li><li><a class="nounderline abstract_t">Petty TL. Definitions in chronic obstructive pulmonary disease. Clin Chest Med 1990; 11:363.</a></li><li class="breakAll">American Thoracic Society / European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. Version 1.2 http://www.thoracic.org/go/copd (Accessed on October 20, 2011).</li><li><a class="nounderline abstract_t">Pu C, Mohan A, Sethi S. Clinical features predict new strain bacterial exacerbation of COPD. Am J Respir Crit Care Med 2019; 199:A5962.</a></li><li><a class="nounderline abstract_t">Vollenweider DJ, Frei A, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018; 10:CD010257.</a></li><li><a class="nounderline abstract_t">Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358:2020.</a></li><li><a class="nounderline abstract_t">Roede BM, Bresser P, Prins JM, et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009; 33:282.</a></li><li><a class="nounderline abstract_t">Rothberg MB, Pekow PS, Lahti M, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010; 303:2035.</a></li><li><a class="nounderline abstract_t">Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181:150.</a></li><li><a class="nounderline abstract_t">Stefan MS, Rothberg MB, Shieh MS, et al. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. Chest 2013; 143:82.</a></li><li><a class="nounderline abstract_t">Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12:CD010257.</a></li><li><a class="nounderline abstract_t">Llor C, Moragas A, Hernández S, et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:716.</a></li><li><a class="nounderline abstract_t">Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11:10.</a></li><li><a class="nounderline abstract_t">Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117:1638.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Kruesmann F, Haverstock D, et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 2012; 39:1354.</a></li><li><a class="nounderline abstract_t">Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103:601.</a></li><li><a class="nounderline abstract_t">Daniels JM, de Graaff CS, Vlaspolder F, et al. Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Clin Microbiol Infect 2010; 16:583.</a></li><li><a class="nounderline abstract_t">Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012; 40:1344.</a></li><li><a class="nounderline abstract_t">Sethi S. Personalised medicine in exacerbations of COPD: the beginnings. Eur Respir J 2012; 40:1318.</a></li><li><a class="nounderline abstract_t">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10:CD007498.</a></li><li><a class="nounderline abstract_t">Daubin C, Valette X, Thiollière F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med 2018; 44:428.</a></li><li><a class="nounderline abstract_t">Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev 2017; 26.</a></li><li><a class="nounderline abstract_t">Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:9.</a></li><li><a class="nounderline abstract_t">Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Butler CC, Gillespie D, White P, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N Engl J Med 2019; 381:111.</a></li><li><a class="nounderline abstract_t">Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 346:988.</a></li><li><a class="nounderline abstract_t">Snow V, Lascher S, Mottur-Pilson C, Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595.</a></li><li><a class="nounderline abstract_t">Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10 Suppl B:3B.</a></li><li><a class="nounderline abstract_t">Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J 2001; 17:928.</a></li><li><a class="nounderline abstract_t">Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61:337.</a></li><li><a class="nounderline abstract_t">Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34:1072.</a></li><li><a class="nounderline abstract_t">Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol 2012; 7:1129.</a></li><li><a class="nounderline abstract_t">Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med 2014; 14:103.</a></li><li><a class="nounderline abstract_t">Boixeda R, Almagro P, Díez-Manglano J, et al. Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2015; 10:2581.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.</a></li><li><a class="nounderline abstract_t">Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin North Am 2004; 18:861.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.</a></li><li><a class="nounderline abstract_t">Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29:1127.</a></li><li><a class="nounderline abstract_t">van Velzen P, Ter Riet G, Bresser P, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. Lancet Respir Med 2017; 5:492.</a></li><li><a class="nounderline abstract_t">Golden AR, Baxter MR, Davidson RJ, et al. Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16. J Antimicrob Chemother 2019; 74:iv39.</a></li><li><a class="nounderline abstract_t">Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132:447.</a></li><li><a class="nounderline abstract_t">Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40:17.</a></li><li><a class="nounderline abstract_t">Nouira S, Marghli S, Besbes L, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis 2010; 51:143.</a></li><li><a class="nounderline abstract_t">Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008; 62:442.</a></li><li><a class="nounderline abstract_t">Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021; 203:24.</a></li><li><a class="nounderline abstract_t">Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; :CD002733.</a></li><li><a class="nounderline abstract_t">Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017; 1:CD001390.</a></li><li><a class="nounderline abstract_t">Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689.</a></li><li><a class="nounderline abstract_t">Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2:361.</a></li><li><a class="nounderline abstract_t">Blasi F, Bonardi D, Aliberti S, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010; 23:200.</a></li><li><a class="nounderline abstract_t">Pomares X, Montón C, Espasa M, et al. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 2011; 6:449.</a></li><li><a class="nounderline abstract_t">Berkhof FF, Doornewaard-ten Hertog NE, Uil SM, et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res 2013; 14:125.</a></li><li><a class="nounderline abstract_t">Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; 10:CD009764.</a></li><li><a class="nounderline abstract_t">Huckle AW, Fairclough LC, Todd I. Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics. Respir Care 2018; 63:609.</a></li><li><a class="nounderline abstract_t">Brill SE, Law M, El-Emir E, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax 2015; 70:930.</a></li></ol></div><div id="topicVersionRevision">Topic 7019 Version 68.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.goldcopd.org" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org www.goldcopd.org (Accessed on November 16, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34570991" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492164" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492164" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659270" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205436" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Definitions in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205436" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Definitions in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical features predict new strain bacterial exacerbation of COPD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30371937" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotics for exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11755608" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047316" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501925" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797691" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235687" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotics for exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923662" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109213" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858396" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034649" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027281" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Relation of sputum colour to bacterial load in acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681947" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523352" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23204018" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Personalised medicine in exacerbations of COPD: the beginnings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025194" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663044" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143877" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218551" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880285" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31291514" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919309" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11281744" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944998" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Canadian guidelines for the management of acute exacerbations of chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488328" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449273" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19386694" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23030418" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pseudomonas infection in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24964956" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26664106" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038881" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Infection in the pathogenesis and course of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15555829" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438350" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17301097" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483402" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505644" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573508" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22135277" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536364" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18467303" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146552" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16437444" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Influenza vaccine for patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28116747" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21864166" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Azithromycin for prevention of exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746000" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20025989" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22003290" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24229360" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376188" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463692" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179246" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
